BD (company)

NextFlex Announces 2024 Fellows Awards for Five Outstanding Recipients

Retrieved on: 
Thursday, March 28, 2024
Hardware, IOT (Internet of Things), Chemicals, Plastics, Automotive Manufacturing, Aerospace, Manufacturing, Government Technology, Technology, Audio, Video, Defense, Military, Science, Telecommunications, Engineering, Research, Manufacturing USA, Tissue engineering, General Electric, USMC, Electrical engineering, Laser, Education, Madhu, Honeywell, Electronics, BD (company), AFRL, Plaque, NASA, STEM, SME, Miniaturization, Sigma, Printed electronics, Multimedia, Lighting, NRO, DARPA, Navy, Air Products, Management

NextFlex®, America's Hybrid Electronics Manufacturing Institute, presented the annual NextFlex Fellow Awards to five deserving individuals in recognition of their exceptional commitment to advanced manufacturing and the additive hybrid electronics member community.

Key Points: 
  • NextFlex®, America's Hybrid Electronics Manufacturing Institute, presented the annual NextFlex Fellow Awards to five deserving individuals in recognition of their exceptional commitment to advanced manufacturing and the additive hybrid electronics member community.
  • A NextFlex Fellow demonstrates leadership and subject matter expertise in support of the NextFlex mission.
  • View the full release here: https://www.businesswire.com/news/home/20240328483614/en/
    Left photo: 2024 Fellows Award recipients are presented with plaques by the NextFlex Co-Executive Directors.
  • These outstanding trailblazers exemplify what’s best about our member community as they help drive the NextFlex mission forward.

Global Prefilled Syringes Market Trends and Forecasts, 2024-2035: Innovations in Prefilled Syringes Address Patient Compliance and Safety Concerns - ResearchAndMarkets.com

Retrieved on: 
Tuesday, March 19, 2024
Pharmaceutical, Health, Medical Supplies, Molecule, Growth, Prevalence, Rheumatoid arthritis, Diabetes, Anaphylaxis, Risk, Patient, Conditional sentence, Purpose, Research, Usability, BD (company), Injury, Glass, Syringe, CDC, Injection, Safety, Privacy, USD, State, Pharmaceutical industry

The global prefilled syringes market size is estimated to grow from USD 3.02 billion in 2024 to USD 4.97 billion by 2035, representing a CAGR of 4.6% during the forecast period 2024-2035.

Key Points: 
  • The global prefilled syringes market size is estimated to grow from USD 3.02 billion in 2024 to USD 4.97 billion by 2035, representing a CAGR of 4.6% during the forecast period 2024-2035.
  • One of the key objectives of this market report was to estimate the current market size, opportunity and the future growth potential of the prefilled syringes market, over the forecast period.
  • The pre-filled syringes market features around 125 prefilled syringes.
  • The current pre-filled syringes market landscape features the presence of 35 players that have the required expertise to develop and manufacture prefilled syringes.

Sprout Social Announces Fourth Quarter 2023 Financial Results Above Guidance Range

Retrieved on: 
Tuesday, February 20, 2024
Online, G2, CFO, SMB, Reddit, Social media, American Honda Motor Company, SPT, Nationwide, Average cost, Growth, Hospital, Sprout, Commerce, The CW, DHL International Aviation ME, Panasonic, BD (company), Parent, ARR, RPO, GAAP, CoStar Group, Brown–Forman, Central Time, Software, Partnership, Video game

CHICAGO, Feb. 20, 2024 (GLOBE NEWSWIRE) -- Sprout Social, Inc. (“Sprout Social”, the “Company”) (Nasdaq: SPT), an industry-leading provider of cloud-based social media management software, today announced financial results for its fourth quarter ended December 31, 2023.

Key Points: 
  • CHICAGO, Feb. 20, 2024 (GLOBE NEWSWIRE) -- Sprout Social, Inc. (“Sprout Social”, the “Company”) (Nasdaq: SPT), an industry-leading provider of cloud-based social media management software, today announced financial results for its fourth quarter ended December 31, 2023.
  • “We’re pleased to share incredibly strong fourth quarter results,” said Justyn Howard, Sprout Social’s CEO and co-founder.
  • Non-GAAP operating income was $1.7 million, compared to $0.6 million in the fourth quarter of 2022.
  • Non-GAAP net income was $1.0 million, compared to $1.8 million in the fourth quarter of 2022.

AHF Urges WHO: Save Critical HIV Tech

Retrieved on: 
Monday, March 4, 2024
Research, General Health, Medical Devices, Healthcare Reform, Infectious Diseases, Public Policy, Advocacy Group Opinion, Health Technology, Science, Biotechnology, AIDS, Health, Government, CD4, AIDS Healthcare Foundation, POC, AHF, BD (company), World Health Organization, Abbott Laboratories, Patient, Diagnosis, WHO, HIV, Viral load, Wind, Immune system

AIDS Healthcare Foundation (AHF) urges the World Health Organization (WHO) to call on manufacturers of vital point-of-care (POC) CD4 equipment, including Abbott Laboratories and Becton Dickinson (BD), to continue production of the HIV testing equipment and any necessary commodities that ensure proper functioning.

Key Points: 
  • AIDS Healthcare Foundation (AHF) urges the World Health Organization (WHO) to call on manufacturers of vital point-of-care (POC) CD4 equipment, including Abbott Laboratories and Becton Dickinson (BD), to continue production of the HIV testing equipment and any necessary commodities that ensure proper functioning.
  • “Working in 46 countries, AHF country teams are seeing the consequences of Abbott’s and BD’s decisions firsthand, particularly in Africa and Asia.
  • CD4 testing shows how HIV damages our immune system since the virus targets and destroys CD4 cells.
  • While CD4 count is not vital for HIV diagnosis, it’s extremely important upon diagnosis, as the patient’s condition may have already progressed to AIDS—thus essential to the HIV continuum of care.

Bioburden Testing Market worth $2.59 billion by 2031 Owing To Increasing Demand for Quality Assurance and Safety Measures - Exclusive Report by Coherent Market Insights

Retrieved on: 
Thursday, February 15, 2024
Merck, Traction, Growth, ELISA, Food, Bioburden, BD (company), Safety, Mass spectrometry, Nutrient, Drink, Medium (website), SGS, Customization, Thermo Fisher Scientific, PCR, Merck Group, Polymerase chain reaction, Environmental remediation

The demand for rapid microbiological testing methods is increasing as they offer numerous advantages, including reduced testing time and improved efficiency.

Key Points: 
  • The demand for rapid microbiological testing methods is increasing as they offer numerous advantages, including reduced testing time and improved efficiency.
  • Their strong market presence and diverse product portfolio contribute to the overall growth of the bioburden testing market.
  • In summary, the bioburden testing market presents significant opportunities, with the consumables segment and aerobic count testing expected to dominate.
  • These market takeaways highlight the key factors influencing the bioburden testing market's growth and offer insights into its future direction.

Bioburden Testing Market worth $2.59 billion by 2031 Owing To Increasing Demand for Quality Assurance and Safety Measures - Exclusive Report by Coherent Market Insights

Retrieved on: 
Thursday, February 15, 2024
Merck, Traction, Growth, ELISA, Food, Bioburden, BD (company), Safety, Mass spectrometry, Nutrient, Drink, Medium (website), SGS, Customization, Thermo Fisher Scientific, PCR, Merck Group, Polymerase chain reaction, Environmental remediation

The demand for rapid microbiological testing methods is increasing as they offer numerous advantages, including reduced testing time and improved efficiency.

Key Points: 
  • The demand for rapid microbiological testing methods is increasing as they offer numerous advantages, including reduced testing time and improved efficiency.
  • Their strong market presence and diverse product portfolio contribute to the overall growth of the bioburden testing market.
  • In summary, the bioburden testing market presents significant opportunities, with the consumables segment and aerobic count testing expected to dominate.
  • These market takeaways highlight the key factors influencing the bioburden testing market's growth and offer insights into its future direction.

Enable Medicine Appoints Kamni Vijay as Chief Executive Officer

Retrieved on: 
Tuesday, February 13, 2024
Data Management, Biotechnology, Technology, Other Health, Health, General Health, Pharmaceutical, Research, Infectious Diseases, Artificial Intelligence, Science, Real-time, Doctor of Philosophy, Multimedia, AI, NIH, Dartmouth College, Growth, Bio-Rad Laboratories, Drug discovery, Entrepreneurship, BD (company), Polymerase chain reaction, COVID-19, UC, University of California, Davis, Molecular and Cellular Biology, Agilent Technologies, BIOS, Patient, Polymerase, PCR, Medicine, Pharmaceutical industry

Enable Medicine , a leader in AI for biological research and drug discovery, has announced the appointment of Kamni Vijay as Chief Executive Officer.

Key Points: 
  • Enable Medicine , a leader in AI for biological research and drug discovery, has announced the appointment of Kamni Vijay as Chief Executive Officer.
  • Mr. Bodapati remains Chairman of the Board and will transition to the role of Chief Strategy Officer.
  • “Kamni Vijay is highly respected in the life sciences and diagnostics industries,” said Elena Viboch, Partner at General Catalyst.
  • “Kamni brings to Enable extensive experience leading high-performing teams and is exactly the type of leader Enable needs as we advance into our next phase of growth,” said Sunil Bodapati, Chairman and Co-Founder, Enable Medicine.

The World Market for Molecular Diagnostics 12th Edition, Featuring Competitive Analysis of Advanced Cell Diagnostics, Berry Genomics, Biocartis, bioMerieux, CareDx, Danaher, Hologic, Illumina & More - ResearchAndMarkets.com

Retrieved on: 
Wednesday, January 10, 2024
Science, Research, Pharmaceutical, Medical Supplies, General Health, Health, Infectious Diseases, Health Technology, Gen-Probe, Polymerase, NGS, Coagulation, Hepatitis, Fungal infection, Medicine, Infection, NAT, Molecular diagnostics, Geography, Urine, Roche, IVD, TB, Respiratory disease, Developed country, Gene, Human leukocyte antigen, Cancer, Prognosis, Single-nucleotide polymorphism, Risk, Polymerase chain reaction, HLA, Safety, COVID-19, Massive parallel sequencing, Immunoassay, Physician, HIV, BD (company), HPV, DSM-IV codes, PCR, AMR, Metabolism, Pharmacokinetics, Diagnosis, Blood, Growth, Vaccine

Recent years saw molecular diagnostics emerge as the fastest growing segment within the global in vitro diagnostics (IVD) market.

Key Points: 
  • Recent years saw molecular diagnostics emerge as the fastest growing segment within the global in vitro diagnostics (IVD) market.
  • This new report reveals that post-pandemic the market remains ripe with opportunity, notably in the areas of infectious diseases, cancer, and transplant diagnostics.
  • Molecular diagnostics has evolved into an essential instrument in clinical medicine, influencing various facets of healthcare.
  • This report evaluates the present configuration of the molecular diagnostics market in cancer, providing insights into prominent products and geographical segmentation.

Molecular HPV Testing: 6.6% Revenue Growth 2023-2028, reports Kalorama Information

Retrieved on: 
Thursday, January 11, 2024
Gen-Probe, World Health Organization, Medicine, Incidence, Molecular diagnostics, Roche, TB, Tuberculosis, Cancer, Workflow, Vaccination, Risk, Infection, Sale, PAP, Cervical cancer, Food, WHO, COVID-19, STI, FDA, HIV, BD (company), HERE, HPV, Treatment, News, Growth, Vaccine

ARLINGTON, Va., Jan. 11, 2024 /PRNewswire-PRWeb/ -- Human papillomavirus (HPV) testing is a key segment of the double-digit, multi-billion-dollar global molecular diagnostic testing market, according to The World Market for Molecular Diagnostics, 12th Edition, a new report published by leading medical market research firm Kalorama Information. The report reveals that through 2028, molecular HPV testing will grow 6.6%—outpacing growth in several other notable molecular testing segments including HIV, STIs, and genetic/inherited diseases.

Key Points: 
  • ARLINGTON, Va., Jan. 11, 2024 /PRNewswire-PRWeb/ -- Human papillomavirus (HPV) testing is a key segment of the double-digit, multi-billion-dollar global molecular diagnostic testing market, according to The World Market for Molecular Diagnostics, 12th Edition , a new report published by leading medical market research firm Kalorama Information.
  • The report reveals that through 2028, molecular HPV testing will grow 6.6%—outpacing growth in several other notable molecular testing segments including HIV, STIs, and genetic/inherited diseases.
  • Today, molecular diagnostics has evolved into an essential instrument in clinical medicine, influencing various facets of healthcare, according to Kalorama Information.
  • Recently growth in molecular diagnostics methods has also been coming from cancer, TB, ISH/ FISH, and other areas.

Respiratory Disease Testing Market Size & Trends Analysis 2023 - ResearchAndMarkets.com

Retrieved on: 
Tuesday, November 28, 2023
Health, General Health, COPD, Prevalence, Medtronic, BD (company), Application, Respiratory disease, Patient, Occupational lung disease, Airway management, USD, Chronic obstructive pulmonary disease, CareFusion, CT scan, Diagnosis, Growth, Respironics, Asthma, NIV, Medical device, Pharmaceutical industry, Medical imaging

The "Respiratory Disease Testing Market Size, Share & Trends Analysis Report By Product (Imaging Tests, Respirometers, Blood Gas Tests), By End-use, By Application, By Region, And Segment Forecasts, 2023 - 2030" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Respiratory Disease Testing Market Size, Share & Trends Analysis Report By Product (Imaging Tests, Respirometers, Blood Gas Tests), By End-use, By Application, By Region, And Segment Forecasts, 2023 - 2030" report has been added to ResearchAndMarkets.com's offering.
  • The global respiratory disease testing market size is expected to reach USD 7.75 billion by 2030, registering a CAGR of 2.8% from 2023 to 2030
    The market is driven by the rising prevalence of respiratory diseases.
  • Along with technological advancements, use of digital radiography (X-ray) and advanced portable spirometers is gaining momentum in the respiratory disease testing/diagnostics market.
  • These players are strong brands in the market as they have elaborate product portfolios in respiratory disease diagnostics market